Fidelity Select Pharmaceuticals Port FPHAX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 29.53  /  −0.14 %
  • Total Assets 1.8 Bil
  • Adj. Expense Ratio
    0.700%
  • Expense Ratio 0.700%
  • Distribution Fee Level Low
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 0.66%
  • Turnover 44%

USD | NAV as of Oct 02, 2024 | 1-Day Return as of Oct 02, 2024, 10:20 PM GMT+0

Morningstar’s Analysis FPHAX

Will FPHAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A strong management team and sound investment process underpin Fidelity Select Pharmaceuticals Port's Morningstar Medalist Rating of Gold.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FPHAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 72.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

23.96 458.3 Mil
Healthcare

Novo Nordisk AS ADR

13.34 255.1 Mil
Healthcare

AstraZeneca PLC ADR

8.80 168.2 Mil
Healthcare

Bristol-Myers Squibb Co

4.96 94.8 Mil
Healthcare

UCB SA

4.75 90.8 Mil
Healthcare

GSK PLC ADR

4.49 85.8 Mil
Healthcare

Merck & Co Inc

4.22 80.7 Mil
Healthcare

Gilead Sciences Inc

3.21 61.4 Mil
Healthcare

Fidelity Cash Central Fund

3.02 57.8 Mil
Cash and Equivalents

Legend Biotech Corp ADR

2.51 48.0 Mil
Healthcare

Sponsor Center